<DOC>
	<DOCNO>NCT02867956</DOCNO>
	<brief_summary>The purpose study evaluate efficacy toxicity apatinib patient platinum resistant refractory ovarian cancer combine etoposide .</brief_summary>
	<brief_title>Apatinib Etoposide Patients With Platinum Resistant Refractory Ovarian Cancer</brief_title>
	<detailed_description>Ovarian cancer lead cause death patient gynecologic malignancy . In case , disease diagnose advanced stage approximately 75 % patient eventually experience disease recurrence . However , overall response rate second-line chemotherapy recurrent ovarian cancer 20-27 % . Therefore , important seek alternative agent improve outcome . Apatinib novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor approve treatment advanced gastric cancer . The preclinical study suggest apatinib may effective cancer ovarian cancer . Therefore , purpose study test efficacy safety study drug apatinib combine standard treatment , etoposide , patient platinum resistant refractory ovarian cancer .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>Histologically pathologically confirm diagnosis epithelial carcinoma ovary . Platinum resistant ovarian cancer ( define relapse within 6 month platinum base chemotherapy ) OR platinum refractory ovarian cancer ( define progress platinum base chemotherapy , except refractory patient first line ) Up three prior chemotherapy , least one platinum base chemotherapy Female , age ≥18 year ≤70 year , sign informed consent . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Measurable disease accord RECIST criterion Patients must life expectancy least 3 month . Patients must adequate organ function define follow criterion : White blood cell count ≥ 3 x 10^9/L , Absolute neutrophil count ( ANC ) ( ≥ 1.0 x 10^9/L ) , Hemoglobin ≥ 80 g/L , Platelets ≥ 70 x 10^9/L Total bilirubin ≤ 1 x upper limit normal ( ULN ) , AST ALT ≤ 2 x ULN Serum creatinine ≤ 1 x ULN Had prior exposure apatinib know allegies excipients . History myocardial infarction , unstable angina , New York Heart Association ( NYHA ) Grade IIIIV within 6 month prior Day 1 . Patients QT interval prolongation Serious , nonhealing wound , active ulcer , bowel obstruction . History abdominal fistula gastrointestinal perforation within 28 day prior Day 1 Evidence bleed diathesis coagulopathy Inadequately control hypertension Major surgical procedure within 28 day prior Day 1 Symptomatic central nervous system ( CNS ) metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Apatinib</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>